by Congenital hyperinsulinism treatment includes medications and surgical procedures to reduce excess insulin release in patients suffering from congenital hyperinsulinism. The condition is characterized by abnormally high level of insulin in the blood which causes recurrent episodes of low blood sugar. Medications such as Diazoxide help reduce insulin release. Some patients also require partial pancreatectomy surgery to remove part of the pancreas releasing excess insulin.
The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing prevalence of congenital hyperinsulinism is a key driver of the market growth. As per the Society for the Study of Inborn Errors of Metabolism, the incidence rate of the condition is estimated to range between 1 in 35,000-50,000 live births worldwide. Early diagnosis and treatment can help improve patient outcomes and avoid long term health complications. This has resulted in increased focus on research and development of advanced treatment solutions. For instance, Medtronic and other key players are conducting clinical trials to evaluate deep brain stimulation as a potential new treatment strategy for refractory congenital hyperinsulinism.
SWOT Analysis
Strength: The high prevalence of congenital hyperinsulinism (CHI) and lack of effective long term treatment options present a major unmet medical need.
Weakness: Limited awareness about the condition leads to late diagnosis. Difficulties in differentiating CHI from other conditions also causes delays.
Opportunity: New drug therapies and advanced medical devices in the pipeline can potentially improve treatment outcomes if approved. Growing research support is expanding understanding of disease pathogenesis.
Threats: Stringent regulatory processes for new drugs and devices increase costs and timelines. Early competition from generic versions once major patents expire can erode market share of leading brands.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth over the forecast period from 2023 to 2030. The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023-2030.
Regional analysis
North America holds the largest share in the global congenital hyperinsulinism treatment market due to high healthcare expenditures, strong presence of leading key players, and availability of advanced treatment options. On the other hand, Asia Pacific is anticipated to grow at the fastest pace driven by improving access to healthcare facilities, launch of generic drugs, and initiatives to spread awareness about rare diseases.
Key players
Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
